Purposeful

Purposeful is a biotech company that integrates AI and human expertise to accelerate the development of treatments for rare diseases by repurposing existing marketed drugs. Their business model focuses on minimizing drug development costs by predicting additional effects of compounds already on the market, reducing experimental needs before identifying promising candidates. They have discovered over 20 promising drug candidates targeting 7 therapeutic areas and collaborate with patient groups, pharmaceutical companies, and academia. Key partnerships include FRAXA for Fragile X Syndrome, BIOEMTECH for Glioblastoma, and Leo Pharma Ltd for inflammatory and dermatology indications. Purposeful's approach leverages AI-driven drug repurposing to address unmet clinical needs in rare diseases, positioning them as an innovative player in the rare disease pharmaceutical development market.